However, CML patients often acquire resistance to imatinib due to the emergence of various mutations in the BCR-ABL gene during treatment, particularly in the region encoding the kinase domain of ABL [18]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.